Sofinnova Ventures Inc
13F Reported Value
ⓘ$1.9B
incl. option notional
Equity Holdings
ⓘ$1.9B
Option Notional
ⓘ$62.2M
$13.8M puts / $48.4M calls
Holdings
57
Latest Filing
2026-06-30
Filing Quarter
Q2 2026
Portfolio Overview
Sofinnova Ventures Inc disclosed 57 positions worth $1.9B in its Form 13F-HR for Q2 2026 — $1.9B in common stock plus $62.2M of put/call option positions (reported at underlying notional value, not premium at risk), led by $NTRA (Natera, Inc.) at 22.5% of the equity portfolio, followed by $VERA and $GMAB. During the quarter the fund opened 13 new positions and exited 30 — including a new stake in $SPTX. The portfolio is most concentrated in Healthcare (100.0% of disclosed assets). All figures are sourced directly from Sofinnova Ventures Inc’s Form 13F-HR filing with the SEC under CIK 1631134.
AI Fund Analysis
ConcentratingSector Allocation
AUM History
Top Equity Holdings by Value
Option Positions
13F rules report options at the value of the underlying shares (notional) — not the premium paid or capital at risk. Shown separately from the equity sleeve above.
Quarterly Activity — Q2 2026
Click any card to unlockTop Holdings
- 53.5#1,383
Quality
$420.8M1,550,280 sh - —
Quality
$119.9M2,793,987 sh - 77.9#59
Quality
$111.1M4,045,215 sh - —
Quality
$88.0M365,341 sh - —
Quality
$79.4M1,904,408 sh - —
Quality
$77.4M3,564,871 sh - —
Quality
$58.9M1,696,752 sh - 34.2
Quality
$57.3M1,717,505 sh - 26.8
Quality
$56.2M2,293,788 sh - 70.4
Quality
$50.5M876,970 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
 Natera, Inc.$NTRA | 53.5#1,383 | $420.8M | 1,550,280 |
 Vera Therapeutics, Inc.$VERA | — | $119.9M | 2,793,987 |
 GENMAB A/S$GMAB | 77.9#59 | $111.1M | 4,045,215 |
 Jazz Pharmaceuticals plc$JAZZ | — | $88.0M | 365,341 |
 Rapport Therapeutics, Inc.$RAPP | — | $79.4M | 1,904,408 |
 Seaport Therapeutics, Inc.$SPTX | — | $77.4M | 3,564,871 |
 ArriVent BioPharma, Inc.$AVBP | — | $58.9M | 1,696,752 |
 Ultragenyx Pharmaceutical Inc.$RARE | 34.2 | $57.3M | 1,717,505 |
 BioAge Labs, Inc.$BIOA | 26.8 | $56.2M | 2,293,788 |
 BRISTOL MYERS SQUIBB CO$BMY | 70.4 | $50.5M | 876,970 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of Sofinnova Ventures Inc's 57 positions.
Showing top 10 of 57 holdings.
Sector Allocation
Healthcare
$1.9B
Full Holdings — Sofinnova Ventures Inc (Q2 2026)
All 57 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $NTRA | Natera, Inc. | $420.8M | 22.5% | +0% | 53.5 |
| 2 | $VERA | Vera Therapeutics, Inc. | $119.9M | 6.4% | +0% | — |
| 3 | $GMAB | GENMAB A/S | $111.1M | 5.9% | +438% | 77.9 |
| 4 | $JAZZ | Jazz Pharmaceuticals plc | $88.0M | 4.7% | -39% | — |
| 5 | $RAPP | Rapport Therapeutics, Inc. | $79.4M | 4.2% | +0% | — |
| 6 | $SPTX | Seaport Therapeutics, Inc. | $77.4M | 4.1% | NEW | — |
| 7 | $AVBP | ArriVent BioPharma, Inc. | $58.9M | 3.1% | +0% | — |
| 8 | $RARE | Ultragenyx Pharmaceutical Inc. | $57.3M | 3.1% | -45% | 34.2 |
| 9 | $BIOA | BioAge Labs, Inc. | $56.2M | 3.0% | +0% | 26.8 |
| 10 | $BMY | BRISTOL MYERS SQUIBB CO | $50.5M | 2.7% | -56% | 70.4 |
| 11 |  $SUPN | SUPERNUS PHARMACEUTICALS, INC. | $48.2M | 2.6% | +9% | 41.9 |
| 12 |  $RYTM | RHYTHM PHARMACEUTICALS, INC. | $45.3M | 2.4% | -9% | 33.9 |
| 13 |  $GILD | GILEAD SCIENCES, INC. | $43.3M | 2.3% | NEW | 57.4 |
| 14 |  $UTHR | UNITED THERAPEUTICS Corp | $41.4M | 2.2% | -52% | 71.3 |
| 15 |  $COGT | Cogent Biosciences, Inc. | $40.1M | 2.1% | -51% | — |
| 16 |  $AXSM | Axsome Therapeutics, Inc. | $39.3M | 2.1% | -25% | 40.8 |
| 17 |  $IMTX | Immatics N.V. | $37.2M | 2.0% | +1% | — |
| 18 |  $DYN | Dyne Therapeutics, Inc. | $36.8M | 2.0% | +1% | — |
| 19 |  $IMNM | Immunome Inc. | $36.5M | 1.9% | +1% | 25.3 |
| 20 |  $IDYA | IDEAYA Biosciences, Inc. | $34.5M | 1.8% | -18% | 36.1 |
| 21 |  $ANAB | ANAPTYSBIO, INC | $33.3M | 1.8% | +99% | 48.4 |
| 22 |  $NKTR | NEKTAR THERAPEUTICS | $32.9M | 1.8% | -7% | 9.7 |
| 23 |  $PHVS | Pharvaris N.V. | $30.5M | 1.6% | +8% | — |
| 24 |  $RCUS | Arcus Biosciences, Inc. | $29.2M | 1.6% | +2% | 8.5 |
| 25 |  $INBX | Inhibrx Biosciences, Inc. | $28.7M | 1.5% | -25% | 30 |
| 26 |  $BMRN | BIOMARIN PHARMACEUTICAL INC | $20.5M | 1.1% | -54% | 58.2 |
| 27 |  $MANE | Veradermics, Inc | $18.3M | 1.0% | +103% | — |
| 28 |  $ALC | ALCON INC | $17.2M | 0.9% | -65% | 54.9 |
| 29 |  $INSM | INSMED Inc | $16.9M | 0.9% | -54% | 39.4 |
| 30 | $RARECALL | Ultragenyx Pharmaceutical Inc. | $16.7M | — | +43% | 34.2 |
| 31 |  $ISRGCALL | INTUITIVE SURGICAL INC | $15.9M | — | NEW | 79.9 |
| 32 |  $GMEDCALL | GLOBUS MEDICAL INC | $15.8M | — | NEW | 79.5 |
| 33 |  $EWTX | Edgewise Therapeutics, Inc. | $15.5M | 0.8% | -1% | — |
| 34 |  $EXELPUT | EXELIXIS, INC. | $13.8M | — | +1% | 76.2 |
| 35 |  $NRIX | Nurix Therapeutics, Inc. | $12.7M | 0.7% | NEW | 6.4 |
| 36 |  $DSGN | Design Therapeutics, Inc. | $12.5M | 0.7% | NEW | — |
| 37 |  $DFTX | Definium Therapeutics, Inc. | $12.0M | 0.6% | -26% | — |
| 38 |  $TRAX | First Tracks Biotherapeutics, Inc. | $11.4M | 0.6% | NEW | — |
| 39 |  $ABT | ABBOTT LABORATORIES | $11.2M | 0.6% | NEW | 65.5 |
| 40 |  $IRON | Disc Medicine, Inc. | $10.7M | 0.6% | +87% | — |
| 41 |  $TENX | TENAX THERAPEUTICS, INC. | $7.3M | 0.4% | +379% | — |
| 42 |  $SION | Sionna Therapeutics, Inc. | $6.4M | 0.3% | NEW | — |
| 43 |  $ABSI | Absci Corp | $3.9M | 0.2% | NEW | 7 |
| 44 |  $MIRM | Mirum Pharmaceuticals, Inc. | $3.2M | 0.2% | +0% | 35 |
| 45 |  $JBIO | Jade Biosciences, Inc. | $2.4M | 0.1% | +0% | — |
| 46 |  $SVRA | Savara Inc | $2.2M | 0.1% | +0% | — |
| 47 |  $PRAX | Praxis Precision Medicines, Inc. | $2.2M | 0.1% | -90% | — |
| 48 |  $SEPN | Septerna, Inc. | $1.6M | 0.1% | +0% | 59.2 |
| 49 |  $OKUR | OnKure Therapeutics, Inc. | $1.5M | 0.1% | +127% | — |
| 50 |  $SGMT | Sagimet Biosciences Inc. | $1.3M | 0.1% | NEW | — |
| 51 |  $WVE | Wave Life Sciences, Inc. | $1.1M | 0.1% | +0% | 7.5 |
| 52 |  $AKTS | Aktis Oncology, Inc. | $1.0M | 0.1% | NEW | — |
| 53 |  $TYRA | Tyra Biosciences, Inc. | $1.0M | 0.1% | -84% | — |
| 54 |  $BOLT | Bolt Biotherapeutics, Inc. | $530,226 | 0.0% | +0% | — |
| 55 |  $NXTC | NextCure, Inc. | $356,246 | 0.0% | +0% | — |
| 56 |  $IMA | ImageneBio, Inc. | $188,116 | 0.0% | +0% | 6.6 |
| 57 |  $HTFL | Heartflow, Inc. | $149,018 | 0.0% | NEW | 34.3 |
New Positions (13)
$SPTX Seaport Therapeutics, Inc.$77.4M$GILD GILEAD SCIENCES, INC.$43.3M$ISRGCALL INTUITIVE SURGICAL INC$15.9M$GMEDCALL GLOBUS MEDICAL INC$15.8M$NRIX Nurix Therapeutics, Inc.$12.7M$DSGN Design Therapeutics, Inc.$12.5M$TRAX First Tracks Biotherapeutics, Inc.$11.4M$ABT ABBOTT LABORATORIES$11.2M$SION Sionna Therapeutics, Inc.$6.4M$ABSI Absci Corp$3.9M$SGMT Sagimet Biosciences Inc.$1.3M$AKTS Aktis Oncology, Inc.$1.0M$HTFL Heartflow, Inc.$149,018Exited Positions (30)
$AZN ASTRAZENECA PLC
$QQQPUT INVESCO QQQ TRUST, SERIES 1$UTHRPUT UNITED THERAPEUTICS Corp
$BIIB BIOGEN INC.
$CELC Celcuity Inc.$CELCPUT Celcuity Inc.$AXSMPUT Axsome Therapeutics, Inc.
$BBIO BridgeBio Pharma, Inc.
$DXCM DEXCOM INC
$PFECALL PFIZER INC
$LQDAPUT Liquidia Corp
$XENE Xenon Pharmaceuticals Inc.Browse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for Sofinnova Ventures Inc including:
Track Sofinnova Ventures Inc's Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for Sofinnova Ventures Inc and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: Sofinnova Ventures Inc
13F Pro is an AI hedge fund tracker and stock research platform. For Sofinnova Ventures Inc (SEC CIK: 1631134), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in Sofinnova Ventures Inc's portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.